摘要
多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤。对于适合移植的患者,自体干细胞移植(autologous stem cell transplantation,ASCT)能明显提高深度缓解率并延长无进展生存期。过去十年间,随着对疾病生物学的深入理解和治疗方法的进步,许多MM患者的病情得以控制,生活质量改善,但患者最终仍面临复发困境。针对复发/难治性多发性骨髓瘤(relapsed/refractory multiple myeloma,RRMM)患者,嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞疗法展示出很好的疗效与安全性,显著延缓了疾病进展。本文主要介绍CAR-T细胞疗法在MM治疗中的现状、进展及其治疗失败的原因,以期为CAR-T细胞疗法在MM中进一步发展提供新思路。
Multiple myeloma(MM)is an incurable haematological malignancy of the blood system.For patients suitable for transplan-tation,autologous stem cell transplantation(ASCT)can significantly enhance the rate of remission and prolong progression-free survival.Over the past decade,with a deeper understanding of the disease biology and advances in therapeutic approaches,many MM patients have been able to control disease and improve their quality of life,but they ultimately face the relapse.For patients with relapsed/refractory MM,chimeric antigen receptor T(CAR-T)cell therapy has demonstrated notable efficacy and superior safety,significantly delaying disease progression.This review focuses on the current status and progress of CAR-T cell therapy in the treatment of MM,as well as the reasons for its failure,to provide new ideas for the further development of CAR-T cell therapy in MM.
作者
武佳潞
葛夏
陈文明
杨光忠
WU Jialu;GE Xia;CHEN Wenming;YANG Guangzhong(Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical Univesity,Beijing 100020,China)
出处
《中国癌症防治杂志》
CAS
2024年第5期525-531,共7页
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
